BRAINSTORM CELL THERAPEUTICS INC. Operating Lease Liability
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) had Operating Lease Liability of $113.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-08-14
- 2026-06-30: Operating Lease, Liability $113.00K.
- 2026-03-31: Operating Lease, Liability $159.00K.
- 2025-12-31: Operating Lease, Liability $208.00K.
- 2025-09-30: Operating Lease, Liability $326.00K.
| Period end | Operating Lease, Liability |
|---|---|
| 2026-06-30 | $113.00K 10-Q · filed 2026-08-14 |
| 2026-03-31 | $159.00K 10-Q · filed 2026-05-15 |
| 2025-12-31 | $208.00K 10-Q · filed 2026-08-14 |
| 2025-09-30 | $326.00K 10-Q · filed 2025-11-14 |
| 2025-06-30 | $476.00K 10-Q · filed 2025-08-14 |
| 2025-03-31 | $570.00K 10-Q · filed 2025-05-15 |
| 2024-12-31 | $720.00K 10-K · filed 2026-03-31 |
| 2024-09-30 | $841.00K 10-Q · filed 2024-11-14 |
| 2024-06-30 | $962.00K 10-Q · filed 2024-08-14 |
| 2024-03-31 | $1.12M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $1.27M 10-K · filed 2025-03-31 |
| 2023-09-30 | $2.89M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $3.29M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $3.68M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $4.09M 10-K · filed 2024-04-01 |
| 2022-09-30 | $4.38M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $4.74M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $5.56M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $5.08M 10-K · filed 2023-03-30 |
| 2021-09-30 | $5.50M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $6.04M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $6.48M 10-Q · filed 2021-04-26 |
| 2020-12-31 | $7.22M 10-K · filed 2022-03-28 |
| 2020-09-30 | $1.50M 10-Q · filed 2020-10-15 |
| 2020-06-30 | $1.78M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $2.02M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $2.37M 10-K · filed 2021-02-04 |
| 2019-09-30 | $2.63M 10-Q · filed 2019-11-14 |
| 2019-06-30 | $2.84M 10-Q · filed 2019-08-13 |
| 2019-03-31 | $3.04M 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |